COVID-19 pandemic has emerged since December 2019, causing over 600 million infected cases and 6 million deaths globally (Oct. 2022). COVID-19 is an infectious disease caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), which mutates into several variants, including alpha, beta, delta, gamma, lambda, mu, omicron. Omicron variant recently overtook the previous dominant variant for its high levels of immune evasion and transmissibility. According to the characteristics of SARS-CoV-2, a variety of antivirals have been under research for COVID-19 therapy.
Fig. 1 SARS-CoV-2 Genome and Proteins (PDB-101)
BOC Sciences provides customers with high-quality SARS-CoV-2 inhibitors and relevant pharmaceutical formulation study. Based on the properties of drug candidates, Our R&D center could customize the research program for COVID-19 new drug development.
BOC Sciences has leading formulation technology platforms to support COVID-19 drug development. There are two main areas of COVID-19 drug formulation research.
For some broad-spectrum antiviral agents, we focus on developing new formulation to enhance the efficacy for SARS-CoV-2.
We study the mechanism, pharmacokinetics, toxicology, Drug-Drug Interaction (DDI) and side effects of two or more drugs, and develop the formulation for drug combination to obtain excellent synergistic effect for COVID-19 treatment. e.g. PAXLOVIDTM is an antiviral drug consisting of 150 mg nirmatrelvir and 100 mg ritonavir. Ritonavir essentially shuts down the metabolism of nirmatrelvir in the liver, so that it doesn't move out of your body as quickly, which means it can work longer—giving it a boost to help fight the infection.
BOC Sciences offers professional services of COVID-19 drug development raging from compound screening, druggability assessment to clinical trials. We are committed to giving best solutions to customers in drug research and development.